RT Journal Article
T1 Clinical Efficacy of Two Different Methods to Initiate Sensor-Augmented Insulin Pumps: A Randomized Controlled Trial.
A1 Moreno-Fernandez, Jesus
A1 Gomez, Francisco Javier
A1 Galvez Moreno, Maria Angeles
A1 Castaño, Justo P
AB Aim. To analyze clinical effect of a novel approach to initiate sensor-augmented insulin pumps in type 1 diabetes mellitus (T1DM) patients through early real-time continuous glucose monitoring (RT-CGM) initiation. Methods. A 26-week pilot study with T1DM subjects randomized (1 : 1) to start RT-CGM three weeks before continuous subcutaneous insulin infusion (CGM pre-CSII) or adding RT-CGM three weeks after continuous subcutaneous insulin infusion (CGM post-CSII). Results. Twenty-two patients were enrolled with a mean age of 36.6 yr. (range 19-59 yr.) and T1DM duration of 16.8 ± 10.6 yr. Higher adherence in CGM pre-CSII patients was confirmed at study end (84.6 ± 11.1% versus 64.0 ± 25.4%; P = 0.01). The two intervention groups had similar HbA1c reduction at study end of -0.6% (P = 0.9). Hypoglycemic event frequency reduction was observed from baseline to study end only in CGM pre-CSII group (mean difference in change, -6.3%; 95% confidence interval, -12.0 to -0.5; P = 0.04). Moreover, no severe hypoglycemia was detected among CGM pre-CSII subjects during the study follow-up (0.0 ± 0.0 events versus 0.63 ± 1.0 events; P = 0.03). CGM pre-CSII patients showed better satisfaction than CGM post-CSII patients at the end of the study (27.3 ± 9.3 versus 32.9 ± 7.2; P = 0.04). Conclusions. CGM pre-CSII is a novel approach to improve glycemic control and satisfaction in type 1 diabetes sensor-augmented pump treated patients.
PB Hindawi Limited
YR 2016
FD 2016-11-02
LK http://hdl.handle.net/10668/10705
UL http://hdl.handle.net/10668/10705
LA en
NO Moreno-Fernandez J, Gómez FJ, Gálvez Moreno MÁ, Castaño JP. Clinical Efficacy of Two Different Methods to Initiate Sensor-Augmented Insulin Pumps: A Randomized Controlled Trial. J Diabetes Res. 2016;2016:4171789
NO The authors are very grateful to Dr. Jose M. Tenías (Investigation Support Unit, Mancha Centro Hospital, Alcazar de San Juan, Ciudad Real, Spain) for advice and assistance in preparing the study protocol and database design and help in data analysis. The authors are also very grateful to Marta Gazquez and Marta Pedroche (Registered Nurses, La Mancha-Centro hospital, Alcazar de San Juan, Ciudad Real, Spain) for their support in administering the CSII and RTCGM diabetes educational program. Independent support for this work was provided by Fundacion Sociosanitaria de Castilla-La Mancha (PI-2009/24, Spain). Funding was provided by MINECO (BFU2013-43282-R), Junta de Andalucía (BIO-0139), and CIBERobn. CIBER is an initiative of Instituto de Salud Carlos III, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain
DS RISalud
RD Apr 5, 2025